Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F21%3A10429926" target="_blank" >RIV/00216208:11130/21:10429926 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/21:10429926

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NbM_xicM6b" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NbM_xicM6b</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2021.1961236" target="_blank" >10.1080/10428194.2021.1961236</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis

Popis výsledku v původním jazyce

Our study represents the first description of PAP, a novel early marker for AAP risk prediction, in pediatric patients with ALL and AAP, detection of which could potentially lead to individual patient therapy tailoring. By identifying patients susceptible to AAP and avoiding its severe manifestations, L-asparaginase truncation could be eschewed, which could eventually result in an improvement of patients&apos; overall outcome. We propose that patients with elevated PAP levels should be closely monitored for possible AAP development. Frequent measurements of PAP and AAP diagnostic markers should be exploited, predominantly in treatment protocols with serial L-asparaginase administrations, together with the early use of imaging methods when clinical symptoms appear. Last but not least, we believe that the presented data will stimulate additional larger studies addressing this important question.

Název v anglickém jazyce

Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis

Popis výsledku anglicky

Our study represents the first description of PAP, a novel early marker for AAP risk prediction, in pediatric patients with ALL and AAP, detection of which could potentially lead to individual patient therapy tailoring. By identifying patients susceptible to AAP and avoiding its severe manifestations, L-asparaginase truncation could be eschewed, which could eventually result in an improvement of patients&apos; overall outcome. We propose that patients with elevated PAP levels should be closely monitored for possible AAP development. Frequent measurements of PAP and AAP diagnostic markers should be exploited, predominantly in treatment protocols with serial L-asparaginase administrations, together with the early use of imaging methods when clinical symptoms appear. Last but not least, we believe that the presented data will stimulate additional larger studies addressing this important question.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV18-07-00129" target="_blank" >NV18-07-00129: Význam metabolizmu leukemických buněk při manifestaci onemocnění, jeho progresi a odpovědi na terapii</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

62

Číslo periodika v rámci svazku

14

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

3506-3510

Kód UT WoS článku

000683204900001

EID výsledku v databázi Scopus

2-s2.0-85112096353